Esperion Therapeutics, Inc. (ESPR)
NASDAQ: ESPR · IEX Real-Time Price · USD
2.210
-0.080 (-3.49%)
At close: Jun 21, 2024, 4:00 PM
2.200
-0.010 (-0.45%)
After-hours: Jun 21, 2024, 7:59 PM EDT

Esperion Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year
20232022202120202019 2018 - 2011
Revenue
116.3375.4878.45227.55148.36
Upgrade
Revenue Growth (YoY)
54.14%-3.79%-65.52%53.37%-
Upgrade
Cost of Revenue
43.2726.9714.222.390
Upgrade
Gross Profit
73.0748.5164.23225.16148.36
Upgrade
Selling, General & Admin
142.52109.08184.99199.6265.85
Upgrade
Research & Development
86.11118.93105.98146.94175.61
Upgrade
Operating Expenses
228.63228.01290.96346.55241.47
Upgrade
Operating Income
-155.56-179.5-226.73-121.4-93.1
Upgrade
Interest Expense / Income
58.9856.8146.3522.678.12
Upgrade
Other Expense / Income
-5.29-2.65-3.98-0.52-4.06
Upgrade
Pretax Income
-209.25-233.66-269.11-143.55-97.17
Upgrade
Net Income
-209.25-233.66-269.11-143.55-97.17
Upgrade
Shares Outstanding (Basic)
10366292727
Upgrade
Shares Outstanding (Diluted)
10366292727
Upgrade
Shares Change
55.26%129.76%5.20%1.42%1.26%
Upgrade
EPS (Basic)
-2.03-3.52-9.31-5.23-3.59
Upgrade
EPS (Diluted)
-2.03-3.52-9.31-5.23-3.59
Upgrade
Free Cash Flow
-135.49-174.83-263.81-86.05-71.29
Upgrade
Free Cash Flow Per Share
-1.31-2.63-9.13-3.13-2.63
Upgrade
Gross Margin
62.81%64.27%81.88%98.95%100.00%
Upgrade
Operating Margin
-133.72%-237.83%-289.02%-53.35%-62.75%
Upgrade
Profit Margin
-179.87%-309.58%-343.04%-63.09%-65.49%
Upgrade
Free Cash Flow Margin
-116.46%-231.64%-336.29%-37.81%-48.05%
Upgrade
EBITDA
-150.11-176.35-222.14-120.33-88.73
Upgrade
EBITDA Margin
-129.03%-233.65%-283.18%-52.88%-59.80%
Upgrade
Depreciation & Amortization
0.160.50.610.550.32
Upgrade
EBIT
-150.27-176.85-222.76-120.88-89.05
Upgrade
EBIT Margin
-129.17%-234.31%-283.96%-53.12%-60.02%
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).